ClinicalTrials.gg
RecruitingNCT06319963Updated Nov 10, 2026

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

A Phase 1/2 interventional study of Two IM injections Lenti-HPV-07 and One IM injection Lenti-HPV-07 in HPV-Related Cervical Carcinoma and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Theravectys S.A.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Theravectys S.A. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 10, 2026Primary completion movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
335th of 678
72 · median 71
Started
2024
with 39 others
Phase 1/2
74 of 834
23 open now
Primary completion
2026-12
later than 51 of 217 live
Registered
733rd of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 335th largest by planned enrollment of the 678 interventional ones that give a count, is one of 40 that started in 2024, is one of 74 in phase 1/2, reaches primary completion later than 51 of the 217 other live ones, and was the 733rd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).

The main questions aim to answer are:

  • Is Lenti-HPV-07 safe?
  • Does Lenti-HPV-07 induce an immune response?

Participants will be assigned to a group based on their cancer type

  • either study drug group A: recurrent and/or metastatic cancer
  • or study drug group B: newly diagnosed with locally advanced cancer

After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.

Read the detailed description

As of 06Nov2025 the recruitment in ARm A of the study (recurrent/metastatic cancers) has been closed to further enrollment, in accordance with the protocol and the study's prespecified operational and/or scientific considerations. No new participants will be enrolled into Arm A, and no additional study drug will be administered within this arm.

03

Conditions studied

  • HPV-Related Cervical Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Keywords

  • HPV16
  • Cervical Cancer
  • Oropharyngeal cancer
  • Immuno-oncotherapy
  • Head and Neck Cancers
  • T-cell vaccine
  • Lentiviral Vector
  • Anti-tumor immunity
  • Early E- and E7 antigens
  • HPV18
  • Human Papillomavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive HPV-related oropharyngeal or cervical cancer
  • performance status of 0 or 1
  • adequate hepatic, renal, pulmonary, and bone marrow/hematological function

Exclusion criteria

Exclusion Criteria:

- with seropositivity for , active virus (HCV) infection, or (HBV) infection

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm A : Refractory newly diagnosed

    Refractory recurrent and/or metastatic cervical or oropharyngeal cancer that is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy).

    Drug: Two IM injections Lenti-HPV-07

  • Experimental
    Arm B : newly diagnosed locally advanced

    Participants who have newly diagnosed locally advanced HPV-related oropharyngeal cancer (defined by AJCC 8th edition \[ie, T1-2N2-N3, T3-T4N0-N3\]) or cervical cancer (stages IB to IVA) that has never been treated with curative intent, and who are candidates to begin an SoC treatment (surgery, radiation therapy with or without chemotherapy).

    Drug: One IM injection Lenti-HPV-07

Interventions

  • DrugTwo IM injections Lenti-HPV-07

    two Lenti-HPV-07 intramuscular injections one month apart

  • DrugOne IM injection Lenti-HPV-07

    a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Frequency, intensity, and relationship of adverse events with vaccine administration per CTCAE v5.0

    Time frame: 12 months after last injection

  2. OBD

    To identify the optimal biological dose (OBD) and schedule for subsequent trials of Lenti-HPV-07

    Time frame: 28 days after last injection

Secondary outcomes

  1. Immunogenicity

    * measure of CD4+ and CD8+ T cell responses specific to E6 or E7 from HPV16 and HPV18 in PBMC * repertoire and clonotype tracking, and cytometric analysis of T cell activation/effector/memory marker

    Time frame: 12 months after last injection

  2. PD-L1 expression

    PD-L1 tumor expression, as measured by composite positive score, by 50% both pre- and post-injection

    Time frame: 12 months after last injection

07

Study locations

4 of 4 sites recruiting
  • Florida Cancer Specialists (from Sarah Canon research Institute)
    Orlando, Florida 32827, United States
    Recruiting
    • Cesar Augusto Perez Batista, MD · Principal investigator
  • Tampa General Hospital
    Tampa, Florida 33606, United States
    Recruiting
    • Noman Ashraf, MD · Principal investigator
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Guilherme Rabinowits, MD · Principal investigator
  • Oklahoma Cancer Specialists and Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
    Recruiting
    • Daron Street, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's planned 28 months is below that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 20, 2024
StartActual
Aug 8, 2024
Primary completionEst.
Dec 2026was Jun 2026
CompletionEst.
Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Dec 2026
Nov 10, 2026
Contact
Study contact changed: d•••@oncobay.com · •••8202→a•••@theravectys.com. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jun 2026→Dec 2026
    Contact Study contact changed: d•••@oncobay.com · •••8202→a•••@theravectys.com. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06319963
Lead sponsor
Theravectys S.A.
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Aug 8, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 10, 2026

Study contacts

Anastasia DEMIDOV
Contact
ademidova@theravectys.com
+33 ext. (0)614515520

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion